
    
      Subjects who complete the 8 week treatment period of the double-blind, placebo-controlled
      study LYC-30937-2001 will have the option of receiving LYC-30397-EC 25 mg PO QD in this
      open-label extension study (LYC-30937-2002). Subjects meeting eligibility criteria will enter
      this open-label extension trial upon completion of the LYC-30937-2001 Week 8 study
      procedures. This open-label extension study will consist of 44 weeks of treatment followed by
      a 2 weeks post-treatment follow-up.
    
  